BioXcel, common stock

BioXcel Therapeutics Announces Reverse Stock Split
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will effect a 1-for-16 reverse stock split of its common stock.
BioXcel Therapeutics advances key clinical trials
NEW HAVEN, Conn. - BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company focused on artificial intelligence-driven neuroscience medicine development, announced today significant progress in its clinical programs for BXCL501.
BioXcel Therapeutics Holds Special Meeting, Approves Reverse Stock Split Plan
BioXcel Therapeutics, Inc. conducted a special meeting of stockholders to decide on crucial matters. The meeting saw the participation of 30,360,492 shares of common stock, either in person or represented by proxy,
BioXcel Therapeutics Provides Clinical and Business Update
Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Developed plans for TRANQUILITY In-Care Phase 3 trial of BXCL501 for agitation associated with Alzheimer’s dementia Enhanced operational and financial flexibility through existing credit amendment Strengthened strategic leadership with recent Board appointments NEW HAVEN,
BioXcel Therapeutics announces 1-for-16 reverse stock split
NEW HAVEN, Conn. - BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company focused on developing medicines in neuroscience through artificial intelligence, has declared a 1-for-16 reverse stock split.
BioXcel Therapeutics provides clinical, business update
BioXcel Therapeutics (BTAI) provided an update on the progress of its late-stage clinical programs for lead neuroscience asset BXCL501, as well
BioXcel Therapeutics Sets 1-for-16 Reverse Stock Split To Regain Nasdaq Listing
(RTTNews) - BioXcel Therapeutics, Inc. (BTAI), Thursday announced a reverse stock split of 1-for-16 to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq ...
What is HC Wainwright’s Forecast for BTAI FY2024 Earnings?
Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of BioXcel Therapeutics in a ...
Nasdaq1mon
BioXcel Therapeutics downgraded to Underperform from Buy at BofA
BofA analyst Alec Stranahan downgraded BioXcel Therapeutics (BTAI) to Underperform from Buy with a price target of 25c, down from $7. The firm cites an “uncertain” agitation market opportunity ...